Search

Novel changes during COVID-19 – transforming a walk-in Eye Casualty to a telephone triage service

With the current pandemic climate due to COVID-19, out of the norm approaches have been adopted in different hospitals across the UK to ensure patient safety. At our Eye Casualty (EC) department at Northampton General Hospital (NGH), we felt the...

How to be ‘appy’ on call: a brief guide to mobile phone applications for the on-call ophthalmologist

One of the unexpected outcomes of the COVID-19 pandemic has been an increased reliance and integration of computer technology within hospital medicine. The need for stricter infection control policies during and after lockdown has seen a boom in technology utilisation....

The sexist lens addressing cataract-induced blindness in women

Ninety percent of the world’s blind population resides in low-income, developing countries [1]. The primary cause of their blindness is cataract, a condition that is easily treatable and unnecessary. A cataract is the clouding of the eye’s lens, often resulting...

In conversation with Captain Gary Dyson

Captain Gary Dyson, Chief Pilot of the Orbis Flying Eye Hospital, spoke to Chris Henson about his 22-year stint flying the plane, its role at the cutting edge of aviation and medical technology, and how Orbis plan to continue to...

Ocular surface special: Ocular manifestations of Stevens-Johnson syndrome

Stevens–Johnson syndrome (SJS) is an uncommon dermatological emergency on the same clinical spectrum as toxic epidermal necrolysis (TEN). SJS is characterised by an acute, immune-mediated attack on the skin and mucous membranes, producing a rapidly progressive erythematous eruption with blistering...

Post-stroke visual impairment: how big is the problem, how do we identify it, what we can do about it, and why does it matter?

In the UK, 100,000 new strokes occur each year, with 1.3 million stroke survivors [1]. This article will focus on post-stroke visual impairment, discussing topics of how common it is, how it can be detected, possible management options and how...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...